Checkpoint inhibitor

DRUG3 trials

Sponsors

Achilles Therapeutics UK Limited, Synthorx, Inc, a Sanofi company, Hellenic Cooperative Oncology Group

Conditions

Autoimmune DiseasesCheckpoint InhibitorImmunotherapyMelanomaMetastasis

Phase 1

ATL001 in Patients With Metastatic or Recurrent Melanoma

TerminatedNCT03997474

Achilles Therapeutics UK LimitedMelanoma

Start: 2019-08-15End: 2024-09-03Updated: 2025-03-07

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

TerminatedNCT04009681

Synthorx, Inc, a Sanofi companyMetastasis

Start: 2019-06-20End: 2025-12-02Updated: 2025-12-15

Unknown Phase

Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease

CompletedNCT04805099

Hellenic Cooperative Oncology GroupAutoimmune Diseases, Checkpoint Inhibitor, Immunotherapy

Start: 2020-11-01End: 2021-02-28Updated: 2021-03-22

Related Papers

437 Optimised achilles VELOS<sup>TM</sup> process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

Regular and Young Investigator Award Abstracts2023-10-311 citations

1312 Identification and validation of immunogenic clonal neoantigens for personalized therapies

Regular and Young Investigator Award Abstracts2023-10-31

Abstract 2155: Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR’245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumors

Cancer Research2023-04-041 citations

179P Early proof of concept of safety and clinical activity of clonal neoantigen-reactive T cells (cNeT)

Immuno-Oncology Technology2022-12-012 citations

481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-0113 citations

543 Sensitive quantification and tracking of the active components of a Clonal Neoantigen T cell (cNeT) therapy: From manufacture to peripheral circulation

Regular and Young Investigator Award Abstracts2021-11-011 citations

Abstract LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced/metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study

Cancer Research2021-07-0123 citations

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.

2021-06-2334 citations

Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products

Cancer Research2020-08-153 citations

Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use

Cancer Research2020-08-15